Seven-year follow-up assessment of cardiac function in NSABP B-31, a randomized trial comparing doxorubicin and cyclophosphamide followed by paclitaxel (ACP) with ACP plus trastuzumab as adjuvant therapy for patients with node-positive, human epidermal growth factor receptor 2-positive breast cancer
Field | Value |
---|---|
Model ID | 12-040-01 |
Model Name | Romond 2012 |
Pubmed ID | 22987084 |
First Author | Romond |
Journal | Journal of Clinical Oncology |
Year | 2012 |
Title | Seven-year follow-up assessment of cardiac function in NSABP B-31, a randomized trial comparing doxorubicin and cyclophosphamide followed by paclitaxel (ACP) with ACP plus trastuzumab as adjuvant therapy for patients with node-positive, human epidermal growth factor receptor 2-positive breast cancer |
Primary Index Condition | Cancer |
Secondary Index Condition | N/A |
Outcome | MACE |
Model Sample Size | 1830 |
Cohort Sample Size | 1830 |
Number of Events | 47 |
Follow-Up Duration | Long (>6 months) |
AUROC | 0.72 |
Calibration Reported | 1 |
Covariates | Age in years; Baseline percent LVEF |
Mesh Terms | To be updated |
Number of Validations | 0 |